



10058597

## Freeform Search

---

<b>Database:</b>	US Pre-Grant Publication Full-Text Database
	US Patents Full-Text Database
	US OCR Full-Text Database
	EPO Abstracts Database
	JPO Abstracts Database
	Derwent World Patents Index
	IBM Technical Disclosure Bulletins

<b>Term:</b>	CD151 and transform\$2	 
--------------	------------------------	--

<b>Display:</b>	<input type="text" value="10"/>	<b>Documents in Display Format:</b>	<input type="text" value="-"/>	<b>Starting with Number</b>	<input type="text" value="1"/>
-----------------	---------------------------------	-------------------------------------	--------------------------------	-----------------------------	--------------------------------

**Generate:** ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

---

Search	Clear	Interrupt
--------	-------	-----------

---

### Search History

---

**DATE:** Wednesday, September 21, 2005   [Printable Copy](#)   [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L1</u>	CD151 and transform\$2	10	<u>L1</u>

END OF SEARCH HISTORY

10058597

s CD151 and cDNA  
L1 51 CD151 AND CDNA

=> s l1 and transform##  
L2 1 L1 AND TRANSFORM##

=> d l2 bib ab kwic

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2003:518818 CAPLUS  
DN 139:83981  
TI Anti-**CD151** monoclonal antibody suppressing cell motility and  
metastasis of cancer cells and producing hybridomas  
IN Hasegawa, Hitoshi  
PA Japan Science and Technology Corporation, Japan  
SO Jpn. Kokai Tokkyo Koho, 7 pp.  
CODEN: JKXXAF

DT Patent  
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003189851	A2	20030708	JP 2001-399170	20011228
PRAI	JP 2001-399170		20011228		

AB Hybridomas prepared from fusion of lymphocytes or spleen cells of mammals transformed with SFA-1/PETA-3 (**CD151**) and myeloma cell line, producing monoclonal antibodies specifically recognizing human **CD151**, and suppressing the motility of RPM14788 cells, and use as inhibitor of metastasis of epithelium cancer, nervous system cancer, or sarcoma, are disclosed. The authors have examined the role of the protein **CD151** in cell motility, invasion and metastasis of cancer cells by using **CD151**-overexpressing cells prepared by transfection of **CD151 cDNA** into three cancer cell lines established from different origins; a human colon cancer RPM14788, a human glioblastoma A172 and a human fibrosarcoma HT1080. Invasion into Matrigel and cell motility of all 3 **CD151**-overexpressing cancer cells were enhanced significantly when compared to control parental cells. Pulmonary metastasis of 2 metastatic **CD151**-overexpressing cancer cell lines, RPM14788/**CD151** and HT1080/**CD151**, was higher than that of control parental cells and was markedly inhibited by anti-**CD151** monoclonal antibody (MAb), SFA1.2B4.

TI Anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas

AB Hybridomas prepared from fusion of lymphocytes or spleen cells of mammals transformed with SFA-1/PETA-3 (**CD151**) and myeloma cell line, producing monoclonal antibodies specifically recognizing human **CD151**, and suppressing the motility of RPM14788 cells, and use as inhibitor of metastasis of epithelium cancer, nervous system cancer, or sarcoma, are disclosed. The authors have examined the role of the protein **CD151** in cell motility, invasion and metastasis of cancer cells by using **CD151**-overexpressing cells prepared by transfection of **CD151 cDNA** into three cancer cell lines established from different origins; a human colon cancer RPM14788, a human glioblastoma A172 and a human fibrosarcoma HT1080. Invasion into Matrigel and cell motility of all 3 **CD151**-overexpressing cancer cells were enhanced significantly when compared to control parental cells. Pulmonary metastasis of 2 metastatic **CD151**-overexpressing cancer cell lines, RPM14788/**CD151** and HT1080/**CD151**, was higher than that of control parental cells and was markedly inhibited by anti-**CD151** monoclonal antibody (MAb), SFA1.2B4.

ST **CD151** monoclonal antibody hybridoma cancer cell motility metastasis suppression

IT Human

(**CD151** from; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Antitumor agents  
Cell migration

Hybridoma  
 CDNA sequences  
 (anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Epithelium  
 (cancer, metastasis of; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Spleen  
 (cells, hybridomas prepared from; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Intestine, neoplasm  
 (colon, cell line, metastasis of; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Sarcoma  
 (fibrosarcoma, cell line, metastasis of; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Animal cell line  
 (human colon cancer RPM14788, hybridomas prepared from; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Lymphocyte  
 (hybridomas prepared from; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Nervous system, neoplasm  
 Sarcoma  
 (metastasis of; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Lung, neoplasm  
 Neoplasm  
 (metastasis; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Antibodies and Immunoglobulins  
 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (monoclonal; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Animal cell line  
 (myeloma, hybridomas prepared from; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT Proteins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (transmembrane, **CD151** (SFA-1/PETA-3); anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

IT 552431-23-9  
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)  
 (nucleotide sequence; anti-**CD151** monoclonal antibody suppressing cell motility and metastasis of cancer cells and producing hybridomas)

=>